Oxycodone Hydrochloride Oral Solution, USP 5 mg/5 mL, a). 5 mL, 50 unit dose cups of 5 mL per cas...
FDA Drug Recall #D-0464-2017 — Class II — January 18, 2017
Recall Summary
| Recall Number | D-0464-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 18, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | VistaPharm, Inc. |
| Location | Largo, FL |
| Product Type | Drugs |
| Quantity | 42,776 unit dose cups and 17,403 bottles |
Product Description
Oxycodone Hydrochloride Oral Solution, USP 5 mg/5 mL, a). 5 mL, 50 unit dose cups of 5 mL per case (NDC No. 66689-401-50), b). 500 mL, 12 bottles per case (NDC No. 66689-403-16), Rx only, Manufactured by VistaPharm, Largo, FL 33771.
Reason for Recall
CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.
Distribution Pattern
Nationwide
Lot / Code Information
a). Lot No. 427900, 426700 (Exp. 11/17), 424800, 423600 (Exp. 10/17), 420800 (09/17), 416300 (08/17), 407700, 407300 (Exp. 06/17), 405900, 403900 (Exp. 05/17) b). Lot No. 426900 (Exp. 11/17), 404700 (Exp. 05/17), 390200 (Exp. 02/17)
Other Recalls from VistaPharm, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0018-2023 | Class II | Pyridostigmine Bromide Oral Solution, USP 60 mg... | Sep 30, 2022 |
| D-0376-2022 | Class II | Clobazam Oral Suspension 2.5 mg/mL, 120 mL bott... | Jan 7, 2022 |
| D-0019-2021 | Class III | NYSTATIN ORAL SUSPENSION, USP 100,000 units per... | Sep 25, 2020 |
| D-1378-2020 | Class III | Nystatin Oral Suspension, USP 100,000 units per... | Jun 23, 2020 |
| D-1377-2020 | Class III | Nystatin Oral Suspension, USP 500,000 units/5mL... | Jun 23, 2020 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.